                         SEQUENCE LISTING

<110>  Immunogen, Inc.
       CARRIGAN, Christina N.
       WHITEMAN, Kathleen R.
       PAYNE, Gillian
       LADD, Sharron
 
<120>  METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY

<130>   2921.015PC01

<140>  PCT/US2012/031544
<141>  2012-03-30

<150>  US 61/471,007
<151>  2011-04-01

<160>  5     

<170>  PatentIn version 3.5

<210>  1
<211>  257
<212>  PRT
<213>  Homo sapiens

<400>  1

Met Ala Gln Arg Met Thr Thr Gln Leu Leu Leu Leu Leu Val Trp Val 
1               5                   10                  15      


Ala Val Val Gly Glu Ala Gln Thr Arg Ile Ala Trp Ala Arg Thr Glu 
            20                  25                  30          


Leu Leu Asn Val Cys Met Asn Ala Lys His His Lys Glu Lys Pro Gly 
        35                  40                  45              


Pro Glu Asp Lys Leu His Glu Gln Cys Arg Pro Trp Arg Lys Asn Ala 
    50                  55                  60                  


Cys Cys Ser Thr Asn Thr Ser Gln Glu Ala His Lys Asp Val Ser Tyr 
65                  70                  75                  80  


Leu Tyr Arg Phe Asn Trp Asn His Cys Gly Glu Met Ala Pro Ala Cys 
                85                  90                  95      


Lys Arg His Phe Ile Gln Asp Thr Cys Leu Tyr Glu Cys Ser Pro Asn 
            100                 105                 110         


Leu Gly Pro Trp Ile Gln Gln Val Asp Gln Ser Trp Arg Lys Glu Arg 
        115                 120                 125             


Val Leu Asn Val Pro Leu Cys Lys Glu Asp Cys Glu Gln Trp Trp Glu 
    130                 135                 140                 


Asp Cys Arg Thr Ser Tyr Thr Cys Lys Ser Asn Trp His Lys Gly Trp 
145                 150                 155                 160 


Asn Trp Thr Ser Gly Phe Asn Lys Cys Ala Val Gly Ala Ala Cys Gln 
                165                 170                 175     


Pro Phe His Phe Tyr Phe Pro Thr Pro Thr Val Leu Cys Asn Glu Ile 
            180                 185                 190         


Trp Thr His Ser Tyr Lys Val Ser Asn Tyr Ser Arg Gly Ser Gly Arg 
        195                 200                 205             


Cys Ile Gln Met Trp Phe Asp Pro Ala Gln Gly Asn Pro Asn Glu Glu 
    210                 215                 220                 


Val Ala Arg Phe Tyr Ala Ala Ala Met Ser Gly Ala Gly Pro Trp Ala 
225                 230                 235                 240 


Ala Trp Pro Phe Leu Leu Ser Leu Ala Leu Met Leu Leu Trp Leu Leu 
                245                 250                 255     


Ser 
    


<210>  2
<211>  771
<212>  DNA
<213>  Homo sapiens

<400>  2
atggctcagc ggatgacaac acagctgctg ctccttctag tgtgggtggc tgtagtaggg       60

gaggctcaga caaggattgc atgggccagg actgagcttc tcaatgtctg catgaacgcc      120

aagcaccaca aggaaaagcc aggccccgag gacaagttgc atgagcagtg tcgaccctgg      180

aggaagaatg cctgctgttc taccaacacc agccaggaag cccataagga tgtttcctac      240

ctatatagat tcaactggaa ccactgtgga gagatggcac ctgcctgcaa acggcatttc      300

atccaggaca cctgcctcta cgagtgctcc cccaacttgg ggccctggat ccagcaggtg      360

gatcagagct ggcgcaaaga gcgggtactg aacgtgcccc tgtgcaaaga ggactgtgag      420

caatggtggg aagattgtcg cacctcctac acctgcaaga gcaactggca caagggctgg      480

aactggactt cagggtttaa caagtgcgca gtgggagctg cctgccaacc tttccatttc      540

tacttcccca cacccactgt tctgtgcaat gaaatctgga ctcactccta caaggtcagc      600

aactacagcc gagggagtgg ccgctgcatc cagatgtggt tcgacccagc ccagggcaac      660

cccaatgagg aggtggcgag gttctatgct gcagccatga gtggggctgg gccctgggca      720

gcctggcctt tcctgcttag cctggcccta atgctgctgt ggctgctcag c               771


<210>  3
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  huMov19 vHC

<400>  3

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Phe Met Asn Trp Val Lys Gln Ser Pro Gly Gln Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile His Pro Tyr Asp Gly Asp Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala His 
65                  70                  75                  80  


Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Phe Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Tyr Asp Gly Ser Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Val Thr Val Ser Ser 
        115             


<210>  4
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  huMov19 vLCv1.00

<400>  4

Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Pro Ala Ile Ile Ser Cys Lys Ala Ser Gln Ser Val Ser Phe Ala 
            20                  25                  30          


Gly Thr Ser Leu Met His Trp Tyr His Gln Lys Pro Gly Gln Gln Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ala Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Lys Thr Asp Phe Thr Leu Asn Ile Ser 
65                  70                  75                  80  


Pro Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Arg 
                85                  90                  95      


Glu Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105                 110         


<210>  5
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  huMov19 vLCv1.60

<400>  5

Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Pro Ala Ile Ile Ser Cys Lys Ala Ser Gln Ser Val Ser Phe Ala 
            20                  25                  30          


Gly Thr Ser Leu Met His Trp Tyr His Gln Lys Pro Gly Gln Gln Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ala Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Lys Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Pro Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Arg 
                85                  90                  95      


Glu Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105                 110         


